1. Home
  2. EOLS

EOLS

Evolus Inc.

Logo Evolus Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Founded: 2012 Country:
United States
United States
Employees: N/A City: NEWPORT BEACH
Market Cap: 710.9M IPO Year: 2018
Target Price: $21.83 AVG Volume (30 days): 590.6K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.08 EPS Growth: N/A
52 Week Low/High: $7.07 - $15.43 Next Earning Date: 05-07-2024
Revenue: $202,085,000 Revenue Growth: 35.98%
Revenue Growth (this year): 31.69% Revenue Growth (next year): 32.57%

Share on Social Networks: